Cancer Research Cell Death Mechanisms and Cancer Therapy  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on September 3, 2008
[Cancer Research, 10.1158/0008-5472.CAN-08-0072]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow All Versions of this Article:
0008-5472.CAN-08-0072v1
68/18/7439    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lebedeva, I. V.
Right arrow Articles by Fisher, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lebedeva, I. V.
Right arrow Articles by Fisher, P. B.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Mechanism of In vitro Pancreatic Cancer Cell Growth Inhibition by Melanoma Differentiation–Associated Gene-7/Interleukin-24 and Perillyl Alcohol

Irina V. Lebedeva 1, Zhao-zhong Su , Nichollaq Vozhilla , Lejuan Chatman , Devanand Sarkar , Paul Dent , Mohammad Athar , Paul B. Fisher *

1 Departments of 1Urology, 2Pathology, 3Dermatology, and 4Neurosurgery, Herbert Irving Comprehensive Cancer Center, Columbia University, College of Physicians and Surgeons, New York, New York and Departments of 5Human and Molecular Genetics and 6Biochemistry and Molecular Biology, 7VCU Institute of Molecular Medicine, and 8Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia

* To whom correspondence should be addressed. E-mail: pbfisher{at}vcu.edu.


   Abstract

The death rate for pancreatic cancer approximates the number of new cases each year, and when diagnosed, current therapeutic regimens provide little benefit in extending patient survival. These dire statistics necessitate the development of enhanced single or combinatorial therapies to decrease the pathogenesis of this invariably fatal disease. Melanoma differentiation–associated gene-7/interleukin-24 (mda-7/IL-24) is a potent cancer gene therapeutic because of its broad-spectrum cancer-specific apoptosis-inducing properties as well as its multipronged indirect antitumor activities. However, pancreatic cancer cells show inherent resistance to mda-7/IL-24 that is caused by a block of translation of mda-7/IL-24 mRNA in these tumor cells. We now reveal that a dietary agent perillyl alcohol (POH) in combination with Ad.mda-7 efficiently reverses the mda-7/IL-24 "protein translational block" by inducing reactive oxygen species, thereby resulting in mda-7/IL-24 protein production, growth suppression, and apoptosis. Pharmacologic inhibitor and small interfering RNA studies identify xanthine oxidase as a major source of superoxide radical production causing these toxic effects. Because both POH and Ad.mda-7 are being evaluated in clinical trials, combining a dietary agent and a virally delivered therapeutic cytokine provides an innovative approach for potentially treating human pancreatic cancer. [Cancer Res 2008;68(18):7439–47]

Key Words: mda-7/IL-24, POH, reactive oxygen species, cancer-selective apoptosis, xanthine oxidase







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.